Zum Hauptinhalt springen

Publikationen

Ausgewähle Publikationen (2015-2018)

2018

Diagnostic potential of major and trace elements in the serum of bladder cancer patients. J Trace Elem Med Biol 2018; 46() Wach S, Weigelt K, Michalke B, Lieb V, Stoehr R, Keck B, Hartmann A, Wullich B, Taubert H, Chaudhri A

A multicenter comparison of PD-L1 protein and mRNA expression in urothelial bladder cancer by immunohistochemistry and RT-qPCR (Checkpoint-Typer(C)): A round robin test by the BRIDGE-Consortium Germany. Oncology Research and Treatment 2018; 41(): 81-81 Eckstein M, Wirtz R, Pfannstil C, Wach S, Stoehr R, Breyer J, Erlmeier F, Guenes C, Nitschke K, Weichert W, Otto W, Keck B, Eidt S, Burger M, Taubert H, Wullich B, Bolenz C, Hartmann A, Erben P

Expression of GP88 (progranulin) in serum of prostate cancer patients is associated with Gleason scores and overall survival. Cancer Manag. Res. 2018; 10(): 4173-4180
Greither T, Fischer K, Theil G, Marcou M, Holzhausen HJ, Weigelt K, Serrero G, Hicks D, Yue BB, Fornara P, Wullich B, Taubert H, Wach S, Lieb V

Non-invasive bladder cancer. Onkologe 2018; 24(1): 23-31 Burger M, Schwaibold H, Goebell P, Grimm MO

Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review. Cochrane Database Syst Rev 2018; (7):
Narayan V, Kahlmeyer A, Dahm P, Skoetz N, Risk MC, Bongiorno C, Patel N, Hwang EC, Jung JH, Gartlehner G, Kunath F

Prognostic models for predicting overall survival in metastatic castration-resistant prostate cancer: a systematic review. World J Urol 2018; (): Pinart M, Kunath F, Lieb V, Tsaur I, Wullich B, Schmidt S, German Prostate Cancer Consortium (DPKK)

2017

Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study. Eur Urol 2017; 72(3): 461-469 Dyrskjøt L, Reinert T, Algaba F, Christensen E, Nieboer D, Hermann GG, Mogensen K, Beukers W, Marquez M, Segersten U, Høyer S, Ulhøi BP, Hartmann A, Stöhr R, Wach S, Nawroth R, Schwamborn K, Tulic C, Simic T, Junker K, Harving N, Petersen AC, Jensen JB, Keck B, Grimm MO, Horstmann M, Maurer T, Steyerberg EW, Zwarthoff EC, Real FX, Malats N, Malmström PU, Ørntoft TF

Is there evidence for a close connection between side of intravesical tumor location and ipsilateral lymphatic spread in lymph node-positive bladder cancer patients at radical cystectomy? Int Urol Nephrol 2017; 49(2): 247-254;  May M, Protzel C, Vetterlein MW, Gierth M, Noldus J, Karl A, Grimm T, Wullich B, Grimm MO, Nuhn P, Bastian PJ, Roigas J, Hadaschik B, Gilfrich C, Burger M, Fisch M, Brookman-May S, Aziz A, Hakenberg OW,

Treatment reality and outcome data of patients with advanced papillary renal cell carcinoma - data from the German prospective RCC-Registry Oncology Research and Treatment 2017; 40(): 96-96; Staehler M, Goebell PJ,Mueller L, Overkamp F, Frank M, Kruggel L, Jaenicke M, Marschner N, RCC Registry Grp

Prognostic factors for overall survival of patients with advanced renal cell carcinoma - data from the German prospective RCC-Registry Oncology Research and Treatment 2017; 40(): 114-114; Goebell PJ, Mueller L, Staehler M, Mueller M, Frank M, Kruggel L, Jaenicke M, Marschner N, RCC Registry Grp

2016

Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. Cancer Cell. 2016 Jul 11;30(1):27-42. doi: 10.1016/j.ccell.2016.05.004. Hedegaard J, Lamy P, Nordentoft I, Algaba F, Høyer S, Ulhøi BP, Vang S, Reinert T, Hermann GG, Mogensen K, Thomsen MBH, Nielsen MM, Marquez M, Segersten U, Aine M, Höglund M, Birkenkamp-Demtröder K, Fristrup N, Borre M, Hartmann A, Stöhr R, Wach S, Keck B, Seitz AK, Nawroth R, Maurer T, Tulic C, Simic T, Junker K, Horstmann M, Harving N, Petersen AC, Calle ML, Steyerberg EW, Beukers W, van Kessel KEM, Jensen JB, Pedersen JS, Malmström PU, Malats N, Real FX, Zwarthoff EC, Ørntoft TF, Dyrskjøt L.

Homozygous G/G variant of SNP309 in the human MDM2 gene is associated with earlier tumor onset in Caucasian female renal cell carcinoma patients.
Oncogenesis 2016; 5(): e205; Stoehr CG, Stoehr R, Wenners A, Hartmann A, Bertz S, Spath V, Walter B, Junker K, Moch H, Hinze R, Denzinger S, Bond EE, Bond GL, Bluemke K, Weigelt K, Lieb V, Nolte E, Fornara P, Wullich B, Taubert H, Wach S

Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status. Tumour Biol 2016; 37(8): 10177-85; Leidinger P, Hart M, Backes C, Rheinheimer S, Keck B, Wullich B, Keller A, Meese E

Loss of expression of the SWI/SNF complex is a frequent event in undifferentiated/dedifferentiated urothelial carcinoma of the urinary tract.
Virchows Arch 2016; 469(3): 321-30; Agaimy A, Bertz S, Cheng L, Hes O, Junker K, Keck B, Lopez-Beltran A, Stöckle M, Wullich B, Hartmann A

HLA-E expression and its clinical relevance in human renal cell carcinoma.
Oncotarget 2016; 7(41): 67360-67372; Seliger B, Jasinski-Bergner S, Quandt D, Stoehr C, Bukur J, Wach S, Legal W, Taubert H, Wullich B, Hartmann A

Assessment of the extent of unpublished studies in prognostic factor research: a systematic review of p53 immunohistochemistry in bladder cancer as an example.
BMJ Open 2016; 6(8): e009972; Sekula P, Pressler JB, Sauerbrei W, Goebell PJ, Schmitz-Dräger BJ

Genetic variation at the 8q24.21 renal cancer susceptibility locus affects HIF binding to a MYC enhancer. Nat Commun 2016; 7(): 13183; Grampp S, Platt JL, Lauer V, Salama R, Kranz F, Neumann VK, Wach S, Stöhr C, Hartmann A, Eckardt KU, Ratcliffe PJ, Mole DR, Schödel J

2015

Piwil 2 expression is correlated with disease-specific and progression-free survival of chemotherapy-treated bladder cancer patients. Mol Med 2015; 21(): 371-80;
Taubert H, Wach S, Jung R, Pugia M, Keck B, Bertz S, Nolte E, Stoehr R, Lehmann J, Ohlmann CH, Stöckle M, Wullich B, Hartmann A

The combined serum levels of miR-375 and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancer. Int J Cancer 2015; 137(6): 1406-16 ; Wach S, Al-Janabi O, Weigelt K, Fischer K, Greither T, Marcou M, Theil G, Nolte E, Holzhausen HJ, Stöhr R, Huppert V, Hartmann A, Fornara P, Wullich B, Taubert H

Clinical outcome of patients with lymph node-positive prostate cancer following radical prostatectomy and extended sentinel lymph node dissection. Urol Int 2015; 94(3): 296-306;Muck A, Langesberg C, Mugler M, Rahnenführer J, Wullich B, Schafhauser W

Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis. BMJ Open 2015; 5(11): e008217; Kunath F, Borgmann H, Blümle A, Keck B, Wullich B, Schmucker C, Sikic D, Roelle C, Schmidt S, Wahba A, Meerpohl JJ

Combination of Autoantibody Signature with PSA Level Enables a Highly Accurate Blood-Based Differentiation of Prostate Cancer Patients from Patients with Benign Prostatic Hyperplasia. PLoS ONE 2015; 10(6): e0128235; Leidinger P, Keller A, Milchram L, Harz C, Hart M, Werth A, Lenhof HP, Weinhäusel A, Keck B, Wullich B, Ludwig N, Meese E

Checkpoint modulation--A new way to direct the immune system against renal cell carcinoma. Hum Vaccin Immunother 2015; 11(5): 1201-8 Bedke J, Kruck S, Gakis G, Stenzl A, Goebell PJ